MAPK1 and acute myeloid leukemia: A screening trial consisting of 82 acute myeloid leukemia (AML) patients revealed that the CRAF p.S427G mutation, rather than the p.I448V mutation, triggers constitutive activation of ERK by activating the CRAF-ERK signaling cascade, even though both mutations are associated with ERK activation [8].